CORMEDIX INC

NASDAQ: CRMD (CorMedix Inc.)

Kemas kini terakhir: 20 jam lalu

4.82

0.16 (3.43%)

Penutupan Terdahulu 4.66
Jumlah Dagangan 3,195,451
Harga / Pendapatan (P/E Ke hadapan) 33.21
Harga / Jualan (P/S) 1.07
Harga / Buku (P/B) 0.800
Julat 52 Minggu
4.65 (-3%) — 13.02 (170%)
Margin Keuntungan 20.81%
Margin Operasi (TTM) 51.49%
EPS Cair (TTM) 0.250
Jumlah Hutang/Ekuiti (D/E MRQ) 0.41%
Nisbah Semasa (MRQ) 4.21
Aliran Tunai Operasi (OCF TTM) -13.57 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -21.07 M
Pulangan Atas Aset (ROA TTM) 8.31%
Pulangan Atas Ekuiti (ROE TTM) 19.87%

AISkor Stockmoo

-0.1
Nilai 30% 0.7
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Hutang rendah. Keuntungan kukuh. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info
Masa 30% -3.4
Daripada analisis teknikal AI kami terhadap carta. info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Corak pembalikan menaik baru-baru ini: Tukul terbalik. info
Aliran bagi Tempoh Pegangan Anda info NA
Sentimen 20% 0.3
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini bercampur atau neutral. info
Wang Pintar 20% 3.5
Aktiviti Orang Dalam info NA
Institusi bersih +5.68% daripada saham dalam pemfailan 13F terkini: 99 pemegang menambah, 90 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat -11.4% dari 31 Aug hingga 30 Oct 2026, 8.4 hari untuk tutup (FINRA). info
Keadaan pasaran dan sektor lemah.
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak tidak sependapat, jadi skor dilemahkan.
Tidak dikira dalam skor
Harga rendah berbanding purata 52 minggunya. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Tiada isyarat jelas daripada sokongan dan rintangan. info
Skor Akhir -0.06

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok CorMedix Inc. Bercampur Menurun

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CRMD - - - 0.800
TRML 1 B - - 4.76
TECH - 0.44% - 5.28
MLTX - - - 2.79
VKTX - - - 6.33
VSTM - - - 76.50

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 1.08%
% Dimiliki oleh Institusi 34.20%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 64.78%

Kedudukan Pemegang Saham
Bertambah 99 7,583,312
Berkurang 90 3,469,708
Baharu 31 1,461,982
Dijual habis 20 1,030,741

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 14,205,973 8.4
15 Oct 2026 14,665,697 12.7
30 Sep 2026 15,422,728 18.9
15 Sep 2026 16,202,272 18.5
31 Aug 2026 16,032,112 13.0
14 Aug 2026 17,149,908 11.1

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

7 Positif 3 Negatif 4 Neutral
Tarikh Jenis Butiran
13 Nov 2026 Yahoo Finance CorMedix's DefenCath, Rezzayo to Drive 2027 Growth, Oppenheimer Says
CorMedix's (CRMD) DefenCath and Rezzayo medications are expected to drive 2027 growth, in addition t…
13 Nov 2026 Yahoo Finance CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.
12 Nov 2026 Yahoo Finance CorMedix Inc. Q3 2026 Earnings Call Summary
Moby summary of CorMedix Inc.'s Q3 2026 earnings call…
12 Nov 2026 Yahoo Finance CorMedix (CRMD) Q3 2026 Earnings Call Transcript
Heron deal and DefenCath reimbursement shifts drive the quarter.
12 Nov 2026 Yahoo Finance What CorMedix (CRMD) Said on Its Q3 Earnings Call
CorMedix (NASDAQ:CRMD) reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron Therapeutics’ assets and deferred 2027 guidance for the dialysis treatment. Revenue fell to $54.5 million fr…
12 Nov 2026 Yahoo Finance CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +55.56% and +3.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
12 Nov 2026 Yahoo Finance CorMedix: Q3 Earnings Snapshot
(CRMD) on Thursday reported a loss of $14.On a per-share basis, the Parsippany, New Jersey-based company said it had a loss of 19 cents.
12 Nov 2026 Yahoo Finance Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million; Adjusted EBITDA of $3.1 million ‒ ‒ Company maintains FY 2026 revenue and narrows Adjusted EBITDA guidance ‒ ‒ Conference call scheduled for…
10 Nov 2026 Yahoo Finance CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio
CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
10 Nov 2026 Yahoo Finance CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings
CorMedix (NASDAQ:CRMD) has agreed to acquire substantially all of Heron Therapeutics’ assets, adding four commercial products and a development agreement to its portfolio of medicines used in hospitals and other institutional settings. CorMedix will pay $145 million in cash and approximately 14.6 m…
09 Nov 2026 Yahoo Finance CorMedix stock gains as Heron deal adds four products
Investing.com -- CorMedix Inc (NASDAQ:CRMD) shares rose 4.5% in premarket trading Monday after the company announced it will acquire substantially all assets of Heron Therapeutics Inc (NASDAQ:HRTX) for approximately $222.6 million. Heron stock surged 45% on the news.
09 Nov 2026 Yahoo Finance CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common…
06 Nov 2026 Yahoo Finance CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
PARSIPPANY, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the third quarter ended September 30, 2026, before the market opens on Thursday, November 12, 2026, and will host a corporate update conference call…
04 Nov 2026 Yahoo Finance Earnings Preview: CorMedix (CRMD) Q3 Earnings Expected to Decline
CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02 Nov 2026 Yahoo Finance CorMedix Reaffirms 2026 Revenue Guidance of $325 Million–$345 Million and Reports $355 Million Cash Position
CorMedix Therapeutics (NASDAQ:CRMD) has maintained its full-year 2026 revenue guidance of $325 million to $345 million and reported approximately $355 million in unaudited cash and cash equivalents as of September 30, 2026, according to a business update released on November 2. The pharmaceutical…
02 Nov 2026 Yahoo Finance CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
PARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s complete quarterly financial performance. Business Updates CorMedix announces…
Papar semua

Isyarat Terkini corak lilin dan silang EMA

▲ Tukul terbalik 2 sesi lalu · 12 Nov
Badan kecil dengan bayang atas yang panjang selepas penurunan: pembeli menguji paras lebih tinggi. Perlu penutupan lebih tinggi untuk pengesahan.

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda